LXRX SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Lexicon Pharmaceuticals Reports Q3 2026 Financial Results and Provides Pipeline Updates

Nov 5, 2026

8-K

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Clinical Pipeline Updates

Aug 6, 2026

8-K

Lexicon Pharmaceuticals Reports Q1 2026 Financial Results and Clinical Pipeline Updates

May 7, 2026

8-K

Lexicon Pharmaceuticals Secures $100 Million Loan Facility with Hercules Capital

May 6, 2026

8-K

Lexicon Pharmaceuticals Announces Conversion of Preferred Stock, Approval of New Equity Incentive Plans, and Authorized Share Increase

Apr 30, 2026

8-K

Lexicon Reports Q4 2025 Financial Results and Provides Pipeline Updates, Highlighting Sotagliflozin Progress and Phase 3 Readiness for Pilavapadin

Mar 5, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Feb 2, 2026

424B5

PENDING FIXED PRICE OFFERING | Bank: Jefferies

Jan 29, 2026

424B5

November 2025 ATM

Nov 6, 2025

424B5

ATM | Offering amount: $75,000,000

Dec 29, 2023

424B5

SHELF OFFERING | Shares amount: 23,924,705 | Share price: $2.60 | Offering amount: $62,204,233.00

Jun 1, 2023

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

May 31, 2023

Registrations

TYPE

HEADLINE

FILED AT

S-3

SHARE RESALE REGISTRATION

Aug 6, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 6, 2026

Form D - Notice of Exempt Offering of Securities - Item 06b

Feb 17, 2026

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Feb 6, 2026

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Jan 30, 2026

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Jan 29, 2026

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Mar 16, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Mar 16, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Feb 17, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 22, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 22, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Mar 25, 2025

Ownerships

TYPE

HEADLINE

FILED AT

NEWExton Michael (Reporting)

Nov 9, 2026

SCHEDULE 13G/A

FMR LLC (Filed by)

Nov 5, 2026

S-3

Form S-3 - Registration statement under Securities Act of 1933

Aug 6, 2026

SCHEDULE 13G/A

FMR LLC (Filed by)

Aug 6, 2026

Swain Judith L (Reporting)

Jun 4, 2026

Sullivan Diane E. (Reporting)

Jun 4, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 17, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 16, 2024

CORRESP

Form CORRESP - Correspondence

Aug 9, 2024

LETTER

Form UPLOAD - SEC-generated letter

Aug 8, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

May 16, 2024

CORRESP

Form CORRESP - Correspondence

May 13, 2024

Lexicon Pharmaceuticals, Inc. LXRX · SEC Filings